ReviewJournal of molecular medicine (Berlin, Germany)2017
The remedy within: will the microbiome fulfill its therapeutic promise?
Review in Journal of molecular medicine (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Epigenetics, bacterial metabolites and type 2 diabetes: a new view of gut-genome interactions.Frontiers in microbiology · 2026Review
- Microbiome therapeutic PMC72 through reverse translational research in gout.Journal of microbiology (Seoul, Korea) · 2025Article
- The relationship between gut microbiome and human diseases: mechanisms, predisposing factors and potential intervention.Frontiers in cellular and infection microbiology · 2025Review
- Model-free prediction of microbiome compositions.Microbiome · 2024Article
- Protective effects of fecal microbiota transplantation against ischemic stroke and other neurological disorders: an update.Frontiers in immunology · 2024Review
- Methods in Nutrition & Gut Microbiome Research: An American Society for Nutrition Satellite Session [13 October 2022].Nutrients · 2023Article
- Metabolic control by the microbiome.Genome medicine · 2022Review
- Microbiome therapeutics: exploring the present scenario and challenges.Gastroenterology report · 2022Review
- Isolation and Characterization of Human Intestinal BacteriaFrontiers in microbiology · 2022Article
- Editorial: From microbial immunology to microbial therapeuticsFrontiers in immunology · 2022Article
- The Gut Microbiome and Bone Strength.Current osteoporosis reports · 2020Review
- Association between the microbiomes of tonsil and saliva samples isolated from pediatric patients subjected to tonsillectomy for the treatment of tonsillar hyperplasia.Experimental & molecular medicine · 2020Article
- Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?Pharmaceutics · 2020Review
- The microbiome-adipose tissue axis in systemic metabolism.American journal of physiology. Gastrointestinal and liver physiology · 2020Review
- An Integrated Multi-Disciplinary Perspectivefor Addressing Challenges of the Human Gut Microbiome.Metabolites · 2020Review
- New Approaches to Microbiome-Based Therapies.mSystems · 2019Article
- Digitalizing the Microbiome for Human Health.mSystems · 2019Article
- A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies.Advances in therapy · 2018Review
- Modulation of Type 1 Diabetes Risk by the Intestinal Microbiome.Current diabetes reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The last decade of research has witnessed a tremendous upsurge in our understanding of the intestinal microbiome and its role in a large range of human diseases, which has incited hopes for a rapid clinical utilization of the new insights for the development of microbiome-based therapies. Nonetheless, only a single microbiome-targeted therapy has so far found its way into clinical routine: fecal microbiota transplantation for patients suffering from recurrent Clostridium difficile infections. Herein, we discuss the current hopes, advances, challenges, and obstacles for translating basic microbiome research into therapeutic applications for a larger number of diseases and provide an outline of how such clinical applications might emerge.
Indexed as
Identifiers
28656322What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.